Compare Regeneron Pharmaceuticals Inc (REGN) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Snap On Incorporated — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B), while Snap On Incorporated trades at $377.53 (market cap $19.65B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4.2× Snap On Incorporated's market cap, and Snap On Incorporated pays the higher dividend (2.57%). Which is the better fit depends on your goals.
| REGN | SNA | |
|---|---|---|
Market Cap | $83.43B | $19.65B |
Sector | Health | Technology |
52-Week High | $852.03 | $419.31 |
52-Week Low | $555.51 | $324.16 |
Enterprise Value | $78.14B | $19.28B |
Dividend Yield | 0.46% | 2.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Snap-On Incorporated (SNA) trades at $379.88, down 0.81% with bearish technical signals but strong fundamentals. The stock shows solid profitability with 19.6% net margins and 17.58% ROE, supported by consistent earnings beats in recent quarters. Recent institutional activity shows mixed positioning while analyst consensus remains bullish with a $473 price target representing 24.5% upside potential.
SNA presents a compelling value opportunity with premium valuation metrics balanced by robust cash flow generation and dividend stability. Key risks include integration challenges from recent acquisitions and potential margin pressure from rising costs. The stock's current technical weakness may offer entry points for long-term investors seeking quality industrial exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
